Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEEL-224 + Vincristine + Temozolomide in Relapsed/Refractory Sarcomas
NCT06709495Phase 2Recruiting
- Start
- Jan 2025
- Primary completion
- Nov 2028
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of PEEL-224 in sarcoma, Ewing sarcoma, desmoplastic small round cell tumor (DSRCT), osteosarcoma (OS), rhabdomyosarcoma (RMS). Started Jan 2025; status: recruiting.
02
Drugs
PEEL-224
03
Conditions
sarcomaEwing sarcomadesmoplastic small round cell tumor (DSRCT)osteosarcoma (OS)rhabdomyosarcoma (RMS)
Beyond the preview
Go deeper on NCT06709495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06709495.